GSK2340273A

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 2

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

CompletedNCT00976820

GlaxoSmithKlineInfluenza

Start: 2009-10-20End: 2011-03-21Updated: 2017-12-12

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

CompletedNCT00985088

GlaxoSmithKlineInfluenza

Start: 2009-10-11End: 2010-12-16Updated: 2017-12-12

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

CompletedNCT00985673

GlaxoSmithKlineInfluenza

Start: 2009-10-01End: 2010-12-29Updated: 2018-08-01

Phase 3

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

CompletedNCT00979602

GlaxoSmithKlineInfluenza

Start: 2009-11-09End: 2011-02-01Updated: 2018-03-21

Related Papers

Non‐neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system

Influenza and Other Respiratory Viruses2020-09-057 citations

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.

2013-07-1232 citations

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

2012-08-0111 citations

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older.

2012-08-0110 citations

Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.

2012-03-0147 citations